论文部分内容阅读
目的探讨益气复脉注射液对肥厚型梗阻性心肌病长期疗效及预后的影响。方法收集2008年5月—2016年5月解放军251医院肥厚型梗阻性心肌病患者124例,随机分为对照组与研究组,每组62例。对照组给予常规治疗,研究组在常规治疗的基础上联合益气复脉注射液治疗,分别于治疗前、治疗后1周、1、3、6、12、24个月观察2组患者的长期疗效及预后差异。结果治疗24个月后,研究组患者复发率为13.9%、总有效率为83.87%,对照组患者复发率33.7%、总有效率32.26%,差异具有统计学意义(P<0.05)。超声心电图结果显示,对照组患者治疗前、后相关指标差异不显著(P>0.05)。研究组患者治疗后较治疗前收缩期二尖辩前叶前向运动分级、左室流出道压力流速、二尖瓣舒张期A峰、E峰、左室等容舒张时间、左室舒张高峰充盈率、左室舒张高峰充盈时间等水平有明显变化,与对照组患者治疗后水平比较有显著改善(P<0.05)。结论益气复脉注射液可改善肥厚型梗阻性心肌病的心舒张功能和减低流出道梗阻,对预后和临床疗效均有显著改善,长期疗效可靠。
Objective To investigate the effect of Yiqi Fumai injection on long-term efficacy and prognosis of hypertrophic obstructive cardiomyopathy. Methods 124 patients with hypertrophic obstructive cardiomyopathy in 251 Hospital of PLA from May 2008 to May 2016 were randomly divided into control group and study group, with 62 patients in each group. The control group was given conventional treatment. The study group was treated with Yiqi Fumai injection on the basis of routine treatment. The patients in both groups were observed before treatment, 1 week after treatment, 1, 3, 6, 12, 24 months respectively Efficacy and prognosis differences. Results After 24 months of treatment, the recurrence rate was 13.9% in the study group, the total effective rate was 83.87%. The recurrence rate was 33.7% in the control group and the total effective rate was 32.26%. The difference was statistically significant (P <0.05). Echocardiography showed that there was no significant difference between the control group before and after treatment (P> 0.05). After treatment, the study group than the treatment before the tip of the anterior scleral movement anterior class, left ventricular outflow tract pressure flow, mitral diastolic peak A, E peak, left ventricular isostatic relaxation time, left ventricular diastolic peak filling Rate, left ventricular diastolic peak filling time and other levels have significant changes, compared with the control group after treatment levels were significantly improved (P <0.05). Conclusion Yiqi Fumai injection can improve the diastolic function of hypertrophic obstructive cardiomyopathy and reduce the obstruction of outflow tract, which has a significant improvement in prognosis and clinical efficacy, and long-term curative effect is reliable.